Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results